Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

34.33 +0.31 (+0.91%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gsk Plc ADR

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
35 36 Next >
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection. 
Via Benzinga
After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US
Via Benzinga
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
Via Benzinga
GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations
Via Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected. 
Via The Motley Fool
Dividend Income Update October 2022
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Peering Into GSK's Recent Short Interest
GSK's (NYSE:GSK) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.7% of all regular shares that are... 
Via Benzinga
Daily Stock Analysis: GSK plc
By my dogcatcher ideal, this is a likely time to buy GSK plc shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
Citing Efficacy, GSK Stops Two Pivotal UTI Antibiotic Trials Early
Via Benzinga
GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat
Shingrix and specialty medicines helped drive GSK's third-quarter growth. 
Via Investor's Business Daily
GSK Lifts Annual Outlook After Robust Vaccines, Specialty Medicine Sales In Q3
Via Benzinga
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care
Via Benzinga
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Deals, financings, trials and approvals in Chinese biotech/biopharma this week. 
Via Talk Markets
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates. 
Via Investor's Business Daily
Moderna's Earnings Collapsed. Time to Sell?
This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills. 
Via The Motley Fool
GSK's Debt Overview
Over the past three months, shares of GSK Inc. (NYSE:GSK) decreased by 16.74%. Before having a look at the importance of debt, let's look at how much debt GSK has. 
Via Benzinga
GSK Pulls Plug On Late-Stage Asset Under Development For Rheumatoid Arthritis
Via Benzinga
GSK One Step Closer To FDA Approval For Anemia Drug For Dialysis Patients
Via Benzinga
Downsizing At Twitter After Musk Takeover, Big Pharma Chains To Pay $14B In Opioid Claims, Tesla Shutters 1st Showroom In China: Top Stories Wednesday, Nov. 02
Reuters 
Via Benzinga
Recap: GSK Q3 Earnings
GSK (NYSE:GSK) reported its Q3 earnings results on Wednesday, November 2, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings GSK beat estimated earnings by 15.63%,... 
Via Benzinga
Earnings This Week: AMD, BP And PayPal
Find out what to expect from this week's earnings calendar. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
GSK Q3 2022 Earnings Conference Call On November 2, 2022 At 08:00 AM ET
GSK (NYSE:GSK) will host a conference call at 08:00 AM ET on November 2, 2022, to discuss Q3 2022 earnings results. How to Attend GSK (GSK) Conference Call Follow this link to access the live webcast. 
Via Benzinga
Is Merck Moving Toward Another Blockbuster Drug Launch?
Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.